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Abstract Many signalling proteins involved in diverse func-
tions such as cell growth and di¡erentiation can act as onco-
genes and cause cellular transformation. These molecules repre-
sent attractive targets for cancer diagnosis or therapy and are
therefore subject to intensive investigation. Aptamers are small
nucleic acid molecules, isolated from combinatorial libraries by
a procedure termed SELEX, that bind to a target molecule by
providing a limited number of speci¢c contact points embedded
in a larger, de¢ned three-dimensional structure. In some cases
aptamers have the potential to inhibit the biological function of
the molecule resulting in useful reagents for target validation in
a variety of disease models. $ 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Changes in the expression of key proteins of the cellular
signalling pathways are at the forefront of molecular abnor-
malities found in cancer. An increasing number of proteins
involved in cell growth, including growth factors, receptors,
intracellular mediators and transcription factors have been
found to be altered through multiple mechanisms of oncogene
activation, such as enhanced or ectopic expression, deletions,
single point mutations and generation of chimeric proteins,
the latter being a consequence of chromosomal translocations.
Many cell surface receptors with an intrinsic intracellular
tyrosine kinase activity can act as oncogenes and cause cellu-
lar transformation [1,2]. For example, epidermal growth fac-
tor receptor is frequently over-expressed in non-small cell lung
carcinoma, bladder, cervical, ovarian, kidney and pancreatic
carcinoma [1,2]. Similarly, over-expression and/or gene ampli-
¢cation of the human epidermal growth factor receptor-re-
lated gene (HER-2)/neu receptor is found in various types
of cancers, including breast (were it occurs in 30% of early
stage cases), ovarian, gastric, lung, bladder, and kidney carci-
nomas [1,2]. Somatic rearrangements of the Ret gene are fre-
quently associated to the papillary histiotype of the thyroid
carcinoma, and germ-line mutations of the Ret receptor cause
inheritance of multiple endocrine neoplasia type 2A and 2B
and familial medullary thyroid carcinoma [1^3]. Single point
mutations which are frequently found in dominant oncogenes
often a¡ect members of the Ras family. Activating mutations
in Ras proteins (accounting for almost 30% of all human
cancers) result in constitutive signalling, thereby stimulating
cell proliferation and inhibiting apoptosis [4]. The BCR/ABL
oncoprotein, generated by a fusion of c-Bcr and the tyrosine
kinase c-Abl, is responsible for a wide range of human leuke-
mias [1,2].
As major molecular determinants of cancer cells, all these
proteins represent primary targets in the rational approach of
the cancer mechanisms. Hence, ¢nding speci¢c ligands capable
to detect and measure their expression is a strategic objective
for the diagnosis and therapy of cancer. These ligands should
have the following characteristics : (i) capacity to discriminate
between oncogenic and non-oncogenic forms of the proteins
involved in signalling pathways; (ii) capacity to quantify the
level of expression of the oncogenic forms; (iii) ideally, be
usable both for in vitro and in vivo purposes; and (iv) ¢nally,
for therapeutic applications the capacity to block the activity
of the oncogene product. To this goal, di¡erent types of mol-
ecules have been shown to be of potential utility for cancer
diagnosis and therapy, including small chemical compounds,
peptides, antibodies and nucleic acid ligands. Here we will
review nucleic acid-based compounds (named aptamers) iso-
lated from combinatorial libraries by an iterative in vitro se-
lection procedure which, in the last few years, has yielded
several high-a⁄nity ligands and potential antagonists of dis-
ease-associated proteins. Aptamers are single-stranded nucleic
acids that, unlike ribozymes and antisense oligonucleotides,
function by folding into a speci¢c globular structure that dic-
tates high-a⁄nity binding to a variety of targets. The cyto-
plasmic expression of aptamers, also called ‘intramers’, has
been recently described demonstrating their striking potential
as rapidly generated intracellular inhibitors of biomolecules
[5]. We will discuss a number of recent non-conventional
and innovative approaches to isolate speci¢c aptamers to tar-
get critical determinants in cancer medicine.
2. SELEX technology to generate nucleic acid aptamers
The starting point for the generation of an aptamer is the
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synthesis of a nucleic acid library (RNA, DNA or modi¢ed
RNA) of large sequence complexity followed by the selection
for oligonucleotides able to bind with high a⁄nity and spec-
i¢city to a target molecule, using a simple procedure called
‘systematic evolution of ligands by exponential enrichment’
(SELEX). Several reviews that describe the SELEX procedure
in detail have appeared [6^11]. Randomization of a sequence
stretch from 22 up to 100 nucleotides in length has been used
to create an enormous diversity of possible sequences which in
consequence generate a vast array of di¡erent conformations
with di¡erent binding properties. The SELEX method in-
cludes steps of (i) incubating the library with the target mol-
ecule under conditions favorable for binding; (ii) partitioning
unbound nucleic acids from those bound speci¢cally to the
selector molecule; (iii) dissociating the nucleic acid^protein
complexes; and (iv) amplifying of the nucleic acids pool en-
riched for speci¢c ligands. After reiterating these steps (the
number of rounds of selection necessary is determined by
both the type of library used as well as by the speci¢c enrich-
ment achieved per selection cycle), the resulting oligonucleo-
tides are subjected to DNA sequencing. The sequences corre-
sponding to the initially variable region of the library are
screened for conserved sequences and structural elements in-
dicative of potential binding sites and subsequently tested for
their ability to bind speci¢cally to the target molecule.
By the SELEX technology, aptamers that bind essentially
any protein or molecule can be generated.
2.1. Puri¢ed proteins as targets
Binding of aptamers to a speci¢c target molecule is concep-
tionally more similar to monoclonal antibodies or small mol-
ecule compounds rather than to antisense oligonucleotides or
ribozymes which are designed to block translation of mRNA
into proteins. Due to the fact that the speci¢c, three-dimen-
sional arrangements of a small number of contact points of
the aptamer mediate the protein^aptamer interaction, rather
than a general a⁄nity for the sugar-phosphate backbone of
the nucleic acid, aptamers can achieve high target selectivity.
In addition, apart from relying on their intrinsic speci¢city
and a⁄nity properties, the binding characteristics of aptamers
can often be in£uenced by the type of the experimental system
used for the selection and counter selection (depletion of ap-
tamers that bind to non-target molecules). The dissociation
constants of aptamers for their targets, which extend usually
from the micromolar to low picomolar range [8,12,13], are
better than those obtained routinely for peptides derived
from phage display experiments and can be comparable to
antibody^antigen interactions.
For example, RNA aptamers have been generated that are
capable of discriminating between isoforms of protein kinase
C [14], a potential target in cancer medicine because of its key
role in cell survival pathways (Table 1). DNA aptamers have
been obtained that recognize both the native and the dena-
tured state of ERK-2, a member of the family of mitogen-
activated protein kinases which are central transducers of
extracellular signals [15]. RNA ligands with high a⁄nity for
the Ras-binding domain (RBD) of Raf-1 have been isolated
and shown to inhibit either Ras binding to Raf-1 or Ras-
induced Raf-1 activation, but they did not a¡ect the interac-
tion of Ras with B-Raf, a Raf-1-related protein [16] (Tables 1
and 2).
2.2. Intact cells as targets
Aptamers that have high a⁄nity and speci¢city for cells and
tissues have also been produced [17], demonstrating that com-
plex targets, including tumor tissue, are compatible with the
SELEX process. Using puri¢ed proteins as targets has the
advantage of easy control of the conditions to achieve optimal
enrichment during the selection process. On the other hand,
‘tissue SELEX’ methodology could be favorable when the
precise molecular target is unknown but the target is, for
example, a speci¢c type of cells. Furthermore, the selection
of the aptamer in a physiological context may reduce the
risk to select aptamers that target protein domains accessible
only in the puri¢ed protein but inaccessible when the protein
is displayed on the cell surface.
Using human red blood cell membranes as model system,
DNA aptamers binding to multiple targets have been isolated
simultaneously [17]. Furthermore, during the selection proce-
dure the puri¢ed protein and the entire cells can also be alter-
Table 1
Reports some examples of aptamers able to inhibit in vitro and/or in vivo the target molecule
Aptamer Target molecule Aptamer activity Diagnostic or therapeutic
application
Ref.
in vitro in vivo
PKC-6 PKC-10 protein kinase
CLII
inhibition of the enzyme
autophosphorylation
nd nd [14]
9A Raf-1 RBD inhibition of the Ras-induced
Raf-1 activation
nd nd [16]
NX1838 VEGF165 inhibition of VEGF binding to
VEGF receptor
inhibition of the VEGF-
induced vascular permeability
administration in humans in
phase-I clinical trials
[22]
PDGF-B
aptamer
PDGF-B inhibition of PDGF binding to
PDGF receptor
reduction of tumor interstitial
£uid pressure
administration in tumor-
bearing rats
[29,30]
NX21909 neutrophil
elastase
inhibition of the enzyme inhibition of lung injury and
neutrophil in£ux
imaging of in£ammation [24]
Toggle-25 thrombin inhibition of plasma clot
formation and platelet
activation
nd nd [32]
XAP anti-NES
antibody
inhibition of binding to the
NES receptor
inhibition of the Rev-dependent
export
nd [35,36]
AL6-A angiogenin inhibition of the ribonucleolytic
activity of angiogenin
nd nd [38]
Where determined, the diagnostic or therapeutic e¡ect of the aptamer is reported. nd, not determined.
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nated as recently described for the isolation of RNA aptamers
against tenascin-C, an extracellular matrix protein over-ex-
pressed during tissue remodelling processes including tumor
growth [18]. As stated in Section 1, tumor-targeting agents
also need to di¡erentiate between normal and malignant
forms of the same tissue, a degree of speci¢city that can be
obtained with aptamers. A £uorescence-based SELEX proce-
dure was applied against transformed endothelial cells as a
complex target to detect microvessels of rat experimental glio-
ma, a fatal brain tumor which is highly vascularized. A sec-
ondary selection scheme, named deconvolution SELEX, was
carried out to facilitate the isolation of ligands for compo-
nents of interest within the targeted mixture [19].
3. In vivo applications of the aptamers
To be of practical use in vivo aptamers must possess de-
¢ned molecular properties, for instance adequate stability in
the biological situation in which it will be employed, or su⁄-
cient systemic clearance in the case of aptamers used as imag-
ing reagents.
3.1. Stability of the aptamers
One of the limitations in the use of aptamers in animal
models of disease and in humans is the reduced stability of
natural nucleic acids in biological media. Major e¡orts have
therefore been directed towards improving the stability of
aptamers by a variety of approaches. Initially, attention is
focused on ‘post-SELEX modi¢cations’, i.e. the substitution
of nucleotides with the corresponding 2P-£uoro, 2P-amino or
2P-O-alkyl variants [9,11,20]. However, due to the fact that
folding rules for single-stranded oligonucleotide regions
change when these modi¢cations are introduced, the binding
properties of an aptamer selected in the presence of standard
nucleotides might be completely di¡erent when the same se-
quence is synthesized with nucleotides containing a di¡erent
2P-substituent [19^21]. To circumvent this limitation selections
can be performed directly in the presence of 2P-modi¢ed nu-
cleotides, as long as the modi¢ed nucleotides are accepted by
T7 RNA polymerase for the in vitro reaction steps of the
selection [21,22].
An interesting application of the SELEX process is based
on the selection of RNA aptamers binding to the mirror-im-
age of an intended target molecule (e.g. an unnatural D-amino
acid peptide), followed by the chemical synthesis of the mir-
ror-image of the selected sequence. As a consequence of mo-
lecular symmetry, the mirror-image aptamer (made from L-
ribose) binds to the natural target molecule. Because of the
substitution of the natural D-ribose with L-ribose, the mirror-
image aptamer (referred as a Spiegelmer) is totally stable. For
example, Spiegelmers that bind to gonadotropin-releasing
hormone I, a decapeptide associated with several malignant
diseases, have been isolated and characterized [23].
3.2. Systemic clearance of the aptamers
Due to their relatively small size (8^15 kDa) in comparison
Fig. 1. Direct in vivo evaluation of oligonucleotide’s pharmaco-distribution by quantitative whole body imaging. An octadeca-oligonucleotide
with an orphan sequence was synthesized in three di¡erent sugar-phosphate backbones and 3P-end labelled with 18F. Positron emission tomog-
raphy was used to visualize in vivo the tissue distribution of the radioactivity following a tracer dose intravenous administration in male adult
baboons. Pharmaco-imaging of aptamers is extremely e¡ective for the quantitative evaluation of their pharmacokinetic parameters.
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to antibodies (150 kDa), aptamers should be better suited for
rapid tumor penetration and blood clearance, two excellent
characteristics for contrast agents in imaging. A notable ex-
ample of aptamer plasticity is represented by the use of the
DNA aptamer inhibitor of the human neutrophil elastase for
in vivo imaging of in£ammation [24] (Table 1). The aptamer
isolated by ‘blended SELEX’ (see below) was labelled with
Technetium-99m and used for imaging in a mouse model.
Remarkably, a better signal-to-noise ratio was achieved by
the aptamer compared to the rat anti-elastase antibody. The
application of aptamers for in vivo imaging is especially
promising due to the very wide range of possibilities available
to introduce changes in their structure through de¢ned chem-
ical modi¢cations that will modify their pharmacokinetic
properties [25] (Fig. 1). For instance, the clearance rates of
aptamers can be altered to keep them in circulation by an-
choring them to liposome bilayers, by coupling them to inert
large molecules such as polyethylene glycol or to other hydro-
phobic groups [26]. There is no experimental evidence so far
for aptamers being immunogenic, a very useful property for
reagents that need to be administered repeatedly to the same
individual for therapy or diagnostic when studying disease
progression.
For diagnostic uses an aptamer should recognize and bind
to a speci¢c target, for therapeutic uses the aptamer has in
addition to be a function-blocking compound and to directly
interrupt the disease process. Aptamers have been reported to
act as direct antagonists of the biological function of proteins
involved in tumor development by competing with the natural
ligands for binding to the same protein domains. Vascular
endothelial growth factor (VEGF) is a central positive regu-
lator of angiogenesis whose expression is elevated in most
solid tumors and in several pathological conditions [27]. Nu-
clease-resistant RNA aptamers speci¢c for the VEGF165 iso-
form potently inhibit the binding of VEGF to the human
receptor in vitro, and one of them (the NX 1838 aptamer)
signi¢cantly reduces intradermal VEGF-induced vascular per-
meability in vivo [22]. NX 1838 is currently the ¢rst therapeu-
tic aptamer to be administered to humans in phase-I clinical
trials (Tables 1 and 2).
The platelet-derived growth factor (PDGF) receptor is ex-
pressed in the stroma of a broad range of solid tumors [28].
An antagonistic PDGF-B aptamer coupled to polyethylene
glycol was used to speci¢cally inhibit the action of PDGF in
a rat model of renal disease [29] and to reduce, by systemic
treatment, tumor interstitial £uid pressure in an experimental
rat colon carcinoma [30] (Table 1).
4. Non-classical approaches to generate aptamers
Recently, the basic SELEX technology has been modi¢ed to
improve the direct use of aptamers in medicine. For example,
the ‘blended SELEX’ process allows to confer high-a⁄nity
binding to a weak, covalent inhibitor of an enzyme. An
RNA library attached covalently to an inhibitory compound
was used to select for a secondary, stabilizing contact for the
target molecule [24].
Modi¢ed DNA aptamers have been generated through a
covalent methodology called ‘photochemical SELEX’ [31] ca-
pable of photocross linking to recombinant basic ¢broblast
growth factor (bFGF), a potent inducer of neovasculariza-
tion, and to distinguish it from the related VEGF and
PDGF (Table 2).
The alternating use of two related target molecules during
the selection (named toggling) creates ligands able to bind to
both targets as recently reported for selection of RNA ap-
tamers that bind to both human and porcine thrombin [32]
(Table 1).
Finally, it has been shown that RNA molecules can form
surfaces that functionally mimic those of proteins [33]. The
strategy based on the so-called anti-idiotype approach uses
antibodies directed against interfaces of protein^protein inter-
actions to isolate from combinatorial libraries, mimics of one
of the interaction domains. This strategy was used to isolate
aptamers binding to a neutralizing antibody directed against
the insulin receptor [34]. Furthermore, an antibody raised
against the HIV-Rev nuclear export signal (NES) has been
used to select ‘export aptamers’ mimicking the NES. These
export aptamers bind to the NES receptor in vitro and inhibit
Rev-dependent export in vivo [35,36] (Table 1). The mimic
selection has now been improved further by combining the
anti-idiotype approach with a strategy related to the ‘blended
SELEX’ to isolate aptamers mimicking the substrate of the
mitogen- and stress-activated protein kinase MSK1. The ob-
tained ‘bi-functional’ substrate mimic binds stably to the ki-
nase and inhibits speci¢cally kinase activity in vitro [37].
5. Concluding remarks
The encouraging results obtained with aptamers combined
with their intrinsic properties and the versatility of the SELEX
procedure should allow the use in diagnostic and even ther-
apeutic applications. The aptamers’ ability to discriminate be-
tween two closely related targets, i.e. between a cancerous cell
and an untransformed cell of the same tissue type, makes
these speci¢c and stable ligands exquisitely suited as imaging
reagents for non-invasive diagnostic procedures. For thera-
peutic applications, aptamers might have to be modi¢ed, for
example by linking them to other molecules, in order to in-
crease their tumor-targeting ability in vivo and, ultimately, to
force their action to inhibit the biological function of the
target. Furthermore, the intracellular delivery of natural and
modi¢ed aptamers is presently at a promising, but still pre-
liminary stage.
It is noteworthy that in addition to use aptamers in cancer
medicine, in the past few years aptamers have been identi¢ed
as powerful antagonists of proteins which are associated with
a number of other diseases [9]. The therapeutic and diagnostic
uses of aptamers will ultimately rely on the identi¢cation of
Table 2
Reports some examples of aptamers able to discriminate between
the selector target protein (italic) and non-target-related proteins
Aptamer Target Kd (nM)
9A Raf-1 RBD 152T23
B-Raf RBD 285T63
06.15 bFGF 0.016
VEGF 16
PDGF 16
NX 1838 human VEGF165 0.049
mouse VEGF164 0.090
human VEGF121 s 1U103
The Kd values of the aptamer^protein complexes are reported.
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molecular targets that are part of a complex macromolecular
machinery that eventually is involved in the disease process.
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